DNV: Partnership

The leadership read

DNV's selection as notified body for Class D in-vitro diagnostic devices commits it to something operationally distinct from lower-risk device certification. Class D carries the highest-risk designation under EU IVDR, blood-screening and infectious-disease diagnostics, and requires the notified body to conduct batch verification and consult EU reference laboratories. DNV is now on the hook for a continuous, science-intensive oversight relationship with a major US manufacturer, not a one-time conformity assessment. The deployment of a digital certification platform signals that DNV is engineering for throughput at scale, because the IVDR transition backlog across the industry is substantial and notified-body capacity has been the binding constraint since the regulation came into force. The related signals in this 90-day window are too scattered across unrelated sectors, consumer brand partnerships, sports-marketing deals, infrastructure JVs, to constitute a coherent regulatory-certification pattern. Taken alone, the DNV signal sits inside a narrower but well-documented story: EU IVDR notified-body capacity has been a recognised bottleneck since 2022, and US manufacturers face compounding pressure as EU market-access deadlines tighten for legacy devices. Companies operating at this intersection of US manufacturing and EU regulatory compliance face rising demand for regulatory-affairs leadership with IVDR-specific depth, quality operations capable of managing third-party notified-body workflows at pace, and market-access strategy capability that can sequence certification priorities across device portfolios under hard deadline pressure.